Premium
Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis
Author(s) -
Ricart José M.,
Ramón Luis A.,
Vayá Amparo,
España Francisco,
Santaolaria MariaLuisa,
Todolí José,
Castelló Remedios,
Fontcuberta Jordi,
Estellés Amparo
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07078.x
Subject(s) - thrombosis , medicine , fibrinolysis , plasminogen activator inhibitor 1 , plasminogen activator , gastroenterology , behcet's disease , immunology , disease
Summary This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) ( P < 0·001) and plasminogen activator inhibitor‐1 (PAI‐1) levels ( P = 0·022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 ( TAFI ) Thr325Ile and SERPINE1 ( PAI1 ) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis ( P = 0·024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.